Filing Analysis
Phio Pharmaceuticals Corp. filed an 8-K to report its financial results for the quarterly period ended June 30, 2026. The filing serves as a formal announcement of the earnings release.
📋 Key Facts
- Reported financial results for the quarter ending June 30, 2026.
- Filing date: August 6, 2026.
- The report includes an earnings press release as Exhibit 99.1.
Phio Pharmaceuticals Corp. announced the appointment of R. Todd Plott, M.D. to its Board of Directors and Governance Committee, effective July 20, 2026.
📋 Key Facts
- Effective date of appointment: July 20, 2026.
- Dr. R. Todd Plott, M.D. appointed to the Board and the Governance Committee.
- Board size increased from five to six members.
- Dr. Plott is a board-certified dermatologist and former FDA advisory committee member with 30+ years of experience.
- Appointment includes standard indemnification agreement and non-employee director compensation/equity awards.
Phio Pharmaceuticals Corp. reported its financial results for the fiscal quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the quarterly period ended March 31, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A press release was issued on May 7, 2026, and included as Exhibit 99.1.
- The company is based in King of Prussia, PA and is listed on the Nasdaq Capital Market under the ticker PHIO.
Phio Pharmaceuticals Corp. entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC to sell up to $6.36 million of its common stock. The company will pay a 3.0% commission on gross proceeds and has no obligation to sell any specific number of shares.
🚩 Red Flags
- Potential for significant shareholder dilution as shares are sold into the open market
- Reliance on equity sales for capital, which is common in micro-cap biotech but can pressure the stock price
📋 Key Facts
- Entered into Sales Agreement on April 8, 2026
- Maximum offering amount of $6,360,000 in common stock
- H.C. Wainwright & Co., LLC acting as the sales agent
- Sales agent will receive a commission of 3.0% of the gross proceeds
- Company agreed to reimburse up to $75,000 for the sales agent's legal counsel fees
- The offering is registered under an existing shelf registration statement on Form S-3 (File No. 333-279557)
Phio Pharmaceuticals announced it has entered into a cGMP drug product manufacturing services agreement with a U.S.-based manufacturer. The agreement is specifically for the production of clinical supply to support the company's ongoing programs.
📋 Key Facts
- The agreement was entered into on March 30, 2026.
- The contract is with a U.S.-based manufacturer for cGMP (Current Good Manufacturing Practice) drug product services.
- The primary purpose of the agreement is to secure clinical supply for the company's drug candidates.
- The filing was made under Item 8.01 (Other Events) rather than Item 1.01.
Phio Pharmaceuticals Corp. reported its financial results for the fiscal year ended December 31, 2025, via a press release on March 5, 2026.
📋 Key Facts
- The company reported financial results for the full year ended December 31, 2025
- The announcement was made on March 5, 2026, and furnished under Item 2.02
- The filing includes a press release as Exhibit 99.1
Phio Pharmaceuticals Corp. entered into a Second Amendment to the employment agreement for President and CEO Robert J. Bitterman on February 17, 2026. The amendment increases his annual target bonus opportunity from 40% to 50% of base salary and adjusts severance terms.
🚩 Red Flags
- Increased severance/bonus packages in micro-cap companies can sometimes signal potential upcoming leadership turnover or management entrenchment.
📋 Key Facts
- Amendment date: February 17, 2026
- CEO Robert J. Bitterman's annual target bonus increased from 40% to 50% of base salary.
- Severance provision amended to provide 12 months of base salary in the event of termination without 'cause' or resignation for 'good reason'.
- The amendment modifies an existing agreement dated February 20, 2023, and a First Amendment dated March 25, 2025.
Phio Pharmaceuticals Corp. announced the formal conclusion of its Safety Medical Committee review regarding the Phase 1b clinical trial of PH-762, alongside updates on clinical trial response rates.
🚩 Red Flags
- Clinical trial safety reviews by a Medical Committee can sometimes imply previous concerns or delays in development timelines.
📋 Key Facts
- The Safety Medical Committee has formally concluded its review of the Phase 1b clinical trial for PH-762.
- The company provided updates regarding clinical trial response rates in a press release dated February 10, 2026.
- The filing includes Exhibit 99.1 containing the full text of the announcement.
Phio Pharmaceuticals Corp. announced positive clinical data from its intratumoral PH-762 dose escalation trial for cutaneous carcinoma. The results showed favorable safety profiles and a high overall response rate in specific cohorts.
📋 Key Facts
- Trial focused on intratumoral PH-762 dose escalation for cutaneous carcinoma.
- Data supports favorable safety and tolerability across all dose escalations.
- Reported 70% overall response rate (ORR) for squamous cell carcinomas.
- Of the 14 responders, 10 reported 100% clearance.
Phio Pharmaceuticals Corp. announced that the FDA has accepted its nonclinical protocol study design for drug candidate PH-762. Toxicology studies are scheduled to begin in Q1 2026.
📋 Key Facts
- FDA acceptance of nonclinical protocol study design for PH-762.
- Toxicology studies expected to commence in the first quarter of 2026.
- The announcement was made via press release on December 23, 2025.
Phio Pharmaceuticals Corp. announced the successful completion of patient enrollment for its ongoing Phase 1b clinical trial involving its siRNA lead compound, PH-762.
📋 Key Facts
- Completion of enrollment in Phase 1b clinical trial (NCT 06014086) on November 25, 2025.
- The trial focuses on the company's siRNA lead compound, PH-762.
- Announcement made via press release issued simultaneously with the 8-K.
Phio Pharmaceuticals Corp. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reported financial results for the quarter ended September 30, 2025.
- Filing date: November 13, 2025.
- The information provided under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Phio Pharmaceuticals Corp. entered into inducement agreements to encourage holders of existing warrants to exercise them at reduced prices, resulting in approximately $13.4 million in gross proceeds. In exchange for this cash infusion, the company is issuing a massive amount of new Series A Warrants, significantly increasing potential future dilution.
🚩 Red Flags
- Significant potential dilution: Issuance of up to 11.3 million new warrant shares represents a massive increase in the float.
- Warrant Inducement/Down-round characteristics: Reducing exercise prices from as high as $5.45 down to $2.05 is highly dilutive to existing shareholders.
- High cost of capital: The combination of reduced exercise prices and significant placement agent fees (8.5% total + warrants) indicates a distressed need for liquidity.
📋 Key Facts
- Total expected gross proceeds from warrant exercises and issuance of New Warrants: ~$13.4 million.
- Existing warrants were exercised at reduced prices (as low as $2.05) to induce immediate cash.
- Company is issuing up to 11,326,364 'New Warrant Shares' via Series A Warrants to holders in exchange for an additional $1.4 million.
- Placement agent H.C. Wainwright & Co., LLC to receive a 7.5% cash fee and 1.0% management fee, plus significant warrants as compensation.
- The offering is being conducted via multiple tranches with initial closings occurring Nov 4 and Nov 6, 2025.
Phio Pharmaceuticals Corp. announced positive clinical data from its Phase 1b dose escalation trial for INTASYL PH-762, showing significant tumor response in three patients with cutaneous squamous cell carcinoma. Additionally, the Safety Monitoring Committee provided a favorable safety review at the maximum dose level.
📋 Key Facts
- Clinical results (Day 36) for cutaneous squamous cell carcinoma: 1 patient showed 100% tumor clearance (Complete Response), 1 patient showed >90% response (Near Complete Response), and 1 patient showed >50% response (Partial Response).
- The Safety Monitoring Committee issued a favorable review of safety data at the maximum dose of INTASYL PH-762.
- Patients completed treatment in the fifth and final dose cohort of the Phase 1b trial (NCT 06014086).
Phio Pharmaceuticals Corp. announced the immediate resignation of Robert Ferrara from the Board of Directors, including his roles on the Compensation and Audit Committees and as Lead Independent Director. The company simultaneously appointed David Deming as the new Lead Independent Director and reduced its total board size from six to five members.
🚩 Red Flags
- Immediate departure of a director holding key committee roles (Audit and Compensation) can sometimes signal internal friction, though the filing explicitly denies disagreement.
📋 Key Facts
- Robert Ferrara resigned effective October 31, 2025.
- Ferrara held positions on the Audit Committee, Compensation Committee, and served as Lead Independent Director.
- The Board of Directors was reduced in size from six (6) members to five (5) members.
- David Deming has been appointed as the new Lead Independent Director.
- The company stated Ferrara's resignation was not due to any disagreement with the Company.
Phio Pharmaceuticals Corp. held its 2025 Annual Meeting of Stockholders on September 11, 2025. Shareholders approved the ratification of Grant Thornton, LLP as independent auditors and an amendment to increase the share pool for the 2020 Long Term Incentive Plan.
🚩 Red Flags
- Significant number of 'Broker Non-Votes' (1,828,465) across multiple proposals, indicating a high level of non-participation or uninstructed proxies which can impact the weight of certain votes in micro-cap governance.
📋 Key Facts
- Annual Meeting held on September 11, 2025.
- Stockholders approved increasing the 2020 Long Term Incentive Plan share pool by 950,000 shares, bringing the total to 1,023,017 shares.
- Grant Thornton, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- All six directors were elected to serve until the 2026 Annual Meeting.
- Shareholders voted for a 3-year frequency for 'Say on Pay' advisory votes.
- The company had 4,798,154 shares outstanding as of the July 18, 2025 record date.
Phio Pharmaceuticals Corp. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference and provided a clinical update regarding its Phase 1b skin cancer trial.
📋 Key Facts
- Company to present at the H.C. Wainwright 27th Annual Global Investment Conference (Sept 8-10, 2025).
- Patients are currently being treated in the 5th cohort of the ongoing Phase 1b clinical trial for skin cancer.
Phio Pharmaceuticals Corp. filed an 8-K to report its financial results for the quarterly period ended June 30, 2025. The filing serves as a formal announcement of the company's recent operational and financial performance.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Filing date: August 14, 2025
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Phio Pharmaceuticals Corp. entered into inducement agreements to facilitate the immediate exercise of existing warrants at a reduced price, raising approximately $2.5 million in gross proceeds. In exchange, the company is issuing significant new Series J and K warrants to holders and placement agent warrants to H.C. Wainwright & Co.
🚩 Red Flags
- Significant dilution risk due to the issuance of nearly 1.86 million new warrant shares (Series J & K).
- Warrant price reduction: Existing warrants were exercised at $2.485, which may be below previous market expectations or fair value.
- Heavy compensation for placement agent including cash fees and significant warrant compensation (7.5% of existing/new warrants).
- Immediate dilution through the issuance of unregistered securities requiring a new registration statement.
📋 Key Facts
- Gross proceeds from warrant exercises expected to be approximately $2.5 million (prior to fees).
- 828,596 existing warrants were exercised at a reduced price of $2.485 per share.
- Issuance of up to 318,596 Series J Warrants and up to 1,538,596 Series K Warrants as inducement.
- New warrants have exercise prices of $2.485 per share with terms ranging from 24 to 60 months.
- H.C. Wainwright & Co., LLC acting as exclusive placement agent with a 7.5% cash fee and 1.0% management fee.
- Company is required to file a Resale Registration Statement within 20 calendar days.
Phio Pharmaceuticals Corp. announced a comprehensive drug substance development services agreement with a U.S.-based manufacturer and reported positive pathology results from its Phase 1b clinical trial for INTASYL PH-762.
📋 Key Facts
- Entered into a comprehensive drug substance development services agreement with a U.S. manufacturing source.
- Released pathology results for four out of five patients in the fourth cohort of the Phase 1b dose escalation clinical trial (NCT 06014086).
- The clinical trial is evaluating the safety and tolerability of neoadjuvant use of INTASYL PH-762.
Phio Pharmaceuticals Corp. has announced the scheduling of its 2025 Annual Meeting of Stockholders for September 11, 2025. Due to a change in the meeting date relative to the previous year's anniversary, the company is providing revised deadlines for stockholder proposals and director nominations.
📋 Key Facts
- 2025 Annual Meeting of Stockholders scheduled for September 11, 2025.
- Record date for voting eligibility: Close of business on July 18, 2025.
- Deadline for Rule 14a-8 stockholder proposals to be included in proxy materials: July 17, 2025.
- Deadline for director nominations or other non-Rule 14a-8 proposals: July 17, 2025.
- Proxy materials are expected to be mailed on or about July 30, 2025.
Phio Pharmaceuticals Corp. announced that its Safety Monitoring Committee has recommended dose escalation to the fifth cohort in its Phase 1b clinical trial (NCT 06014086). This represents a standard progression in early-stage clinical development.
📋 Key Facts
- Safety Monitoring Committee recommendation received on June 25, 2025.
- Clinical trial is a Phase 1b study (NCT 06014086).
- Dose escalation moving to the fifth cohort.
Phio Pharmaceuticals Corp. announced a leadership transition on June 6, 2025, appointing Lisa Carson as the new VP of Finance and Administration (serving as PFO/PAO) and transitioning former CFO Robert Infarinato to VP of Strategic Development.
🚩 Red Flags
- Sudden transition of the CFO/PFO role; while the former CFO remains at the company in a different capacity, the shift in responsibilities for both parties suggests significant organizational restructuring or internal movement.
📋 Key Facts
- Lisa Carson appointed as Principal Financial Officer (PFO) and Principal Accounting Officer (PAO), effective June 6, 2025.
- Ms. Carson's annual base salary is $290,000 with a potential 30% performance bonus.
- A one-time sign-on stipend of $25,000 was provided to Ms. Carson.
- Robert Infarinato ceased serving as PFO/PAO and transitioned from CFO to VP of Strategic Development, effective June 6, 2025.
- Ms. Carson brings experience from Prelude Therapeutics (supported IPO), TELA Bio, and PhaseBio Pharmaceuticals.
Phio Pharmaceuticals Corp. filed an 8-K to report its financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Filing date: May 15, 2025
- The company furnished a press release as Exhibit 99.1 containing the results of operations and financial condition.
Phio Pharmaceuticals Corp. issued a press release regarding clinical trial progress for its drug candidate INTASYL PH-762. The announcement focuses on safety and tolerability results from the third cohort of its Phase 1b dose escalation study.
📋 Key Facts
- Announcement date: May 7, 2025
- Clinical trial focus: Phase 1b dose escalation (NCT 06014086)
- Drug candidate: INTASYL PH-762
- Trial objective: Evaluate safety and tolerability of neoadjuvant use
- Status: Results from the third cohort have been released
Phio Pharmaceuticals Corp. has dismissed its independent auditor, BDO USA, P.C., and appointed Grant Thornton LLP as its new registered public accounting firm for the fiscal year ending December 31, 2025.
🚩 Red Flags
- Auditor change combined with existing 'going concern' language in previous audit reports (FY2023 and FY2024).
- The presence of substantial doubt about the company's ability to continue as a going concern is a critical risk factor for micro-cap companies.
📋 Key Facts
- Dismissal of BDO USA, P.C. effective April 17, 2025.
- Engagement of Grant Thornton LLP effective April 17, 2025.
- BDO's reports for FY2023 and FY2024 included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
- The company stated there were no disagreements with BDO regarding accounting principles or auditing scope that would require disclosure under Regulation S-K.
Phio Pharmaceuticals Corp. announced that its safety monitoring committee has recommended advancing the INTASYL PH-762 clinical program to a fourth dose escalation cohort. This represents positive clinical progress for the company's lead candidate.
📋 Key Facts
- Safety monitoring committee recommendation received on April 9, 2025.
- Clinical program INTASYL PH-762 is advancing to a fourth dose escalation cohort.
- The announcement was made via press release (Exhibit 99.1).
Phio Pharmaceuticals Corp. filed an 8-K to report its financial results for the quarter and fiscal year ended December 31, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reported financial results for the quarter and year ended December 31, 2024.
- Filing date: March 31, 2025.
- The information provided under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Phio Pharmaceuticals Corp. announced the appointment of David H. Deming to its Board of Directors and Nominating Committee, effective February 19, 2025.
📋 Key Facts
- Board size increased from five to six members.
- David H. Deming appointed to the Board until the 2025 annual meeting of stockholders.
- Mr. Deming joins the Nominating Committee.
- Mr. Deming brings over 30 years of experience, including 27 years at JP Morgan in M&A and Health Group leadership.
Phio Pharmaceuticals Corp. completed a registered direct offering and concurrent private placement on January 17, 2025, raising approximately $1.6 million in net proceeds. The deal included the issuance of significant warrants to investors and the placement agent.
🚩 Red Flags
- Significant warrant overhang: Issuance of 1.22M warrants for 610k shares creates substantial potential dilution.
- Warrant pricing: Series I Warrants are exercisable at the same price as the offering ($3.00), providing immediate downside/dilution pressure.
- High cost of capital: Total fees (cash + warrants) represent a significant portion of the gross proceeds.
- Restriction on financing: The company is prohibited from entering variable rate transactions for one year, limiting future flexible financing options.
📋 Key Facts
- Registered Direct Offering: 610,000 shares of common stock at $3.00 per share.
- Private Placement: Issuance of up to 1,220,000 Series I Warrants (2 warrants for every 1 share issued).
- Warrant Terms: Series I Warrants are exercisable at $3.00 per share and expire in 24 months.
- Net Proceeds: Approximately $1.6 million after fees and expenses.
- Placement Agent Fees: H.C. Wainwright & Co., LLC to receive a 7.5% cash fee, 1.0% management fee, plus $30,000 in non-accountable/clearing fees.
- Warrant Overhang: Placement agent received warrants for up to 45,750 shares at an exercise price of $3.75 (125% of offering price).
- Lock-up/Restriction: Company is prohibited from issuing new equity or variable rate transactions until February 1, 2025, and restricted from Variable Rate Transactions until January 17, 2026.
Phio Pharmaceuticals Corp. completed a registered direct offering and concurrent private placement on January 15, 2025, raising approximately $2.2 million in net proceeds. The deal includes the issuance of significant warrants to investors and the placement agent.
🚩 Red Flags
- Significant Warrant Overhang: The issuance of 2 warrants for every 1 share issued (a 2-for-1 warrant ratio) represents substantial potential dilution.
- Warrant Exercise Price: Series H Warrants are exercisable at $3.00, which is the same as the offering price, creating immediate downward pressure upon exercise.
- Placement Agent Compensation: High total compensation structure including cash fees and equity warrants (7.5% of shares).
- Variable Rate Transaction Prohibition: The company is prohibited from entering into Variable Rate Transactions until January 15, 2026.
📋 Key Facts
- Registered Direct Offering: 833,335 shares of common stock at $3.00 per share.
- Private Placement: Issuance of up to 1,666,670 Series H Warrants (2 warrants for every 1 share issued).
- Warrant Terms: Series H Warrants are exercisable at $3.00 per share and expire in 24 months.
- Net Proceeds: Approximately $2.2 million after fees and expenses.
- Placement Agent Fees: H.C. Wainwright & Co., LLC to receive a 7.5% cash fee, 1.0% management fee, plus non-accountable expenses and warrants totaling 62,500 shares (at an exercise price of $3.75).
- Registration Obligation: Company must register 'Warrant Shares' within 30 days and use reasonable efforts to make the registration statement effective within 60 days.
Phio Pharmaceuticals Corp. completed a registered direct offering and concurrent private placement on January 14, 2025, raising approximately $2.85 million in net proceeds. The deal included the issuance of significant warrants to investors and the placement agent.
🚩 Red Flags
- Significant potential dilution: The issuance of Series G Warrants represents a 2-for-1 warrant coverage on the common stock sold.
- Warrant overhang: Large number of warrants (over 2 million) exercisable at $3.00 could create significant downward pressure on the stock price upon exercise.
- High cost of capital: Total fees to placement agent and warrants issued to them represent a high cost for a small raise.
📋 Key Facts
- Registered Direct Offering: 1,063,670 shares of common stock at $3.00 per share.
- Private Placement: Issued up to 2,127,340 Series G Warrants (2 warrants for every 1 share issued).
- Series G Warrants: Exercisable at $3.00 per share; expire in 24 months.
- Net proceeds: Approximately $2.85 million after fees and expenses.
- Placement Agent: H.C. Wainwright & Co., LLC received a 7.5% cash fee, 1.0% management fee, plus $25,000 in non-accountable expenses and $15,950 in clearing fees.
- Placement Agent Warrants: 79,775 shares at an exercise price of $3.75 (125% of offering price).
- The company is prohibited from entering into Variable Rate Transactions until January 14, 2026.
Phio Pharmaceuticals Corp. announced clinical data from the second cohort of its PH-762 study, showing positive efficacy in patients with cutaneous squamous cell carcinoma. The results include 100% tumor clearance in two patients and partial response/stable disease in others.
📋 Key Facts
- Clinical study focused on drug candidate PH-762.
- Cohort 2 data released for 4 completed patients.
- Two patients with cutaneous squamous cell carcinoma achieved complete response (100% tumor clearance).
- One patient showed partial response (90% tumor clearance).
- One patient showed stable disease (no progression).
Phio Pharmaceuticals Corp. completed a registered direct offering and concurrent private placement of 240,000 shares at $2.00 per share, alongside the issuance of warrants to institutional investors.
🚩 Red Flags
- Significant dilution: Issuance of warrants equal to the number of shares sold (1:1 warrant coverage).
- Low net proceeds: Only $480k raised after fees suggests a highly capital-constrained environment.
- Restrictive covenants: One-year prohibition on variable rate transactions and a short-term freeze on other equity issuances until Jan 8, 2025.
- Warrant overhang: Placement agent warrants have an exercise price at a 25% premium ($2.50) to the offering price.
📋 Key Facts
- Registered Direct Offering: 240,000 shares of Common Stock at $2.00 per share.
- Private Placement: Issuance of Series F Warrants to purchase up to 240,000 shares at an exercise price of $2.00 per share.
- Net proceeds are approximately $0.48 million after fees and expenses.
- Placement Agent (H.C. Wainwright & Co., LLC) received a 7.5% cash fee, a 1.0% management fee, and warrants for up to 18,000 shares at an exercise price of $2.50.
- The company is prohibited from entering into variable rate transactions involving common stock until December 23, 2025.
Phio Pharmaceuticals Corp. completed a registered direct offering and concurrent private placement of common stock and warrants to raise approximately $900,000 in net proceeds. The transaction includes the issuance of Series E Warrants to investors and Placement Agent Warrants to H.C. Wainwright & Co., LLC.
🚩 Red Flags
- Significant dilution potential due to the issuance of nearly 874,000 new shares via common stock and warrants.
- Warrant exercise prices ($2.51 for Series E) are below the offering price ($2.635), creating immediate downward pressure upon exercise.
- The company is restricted from certain equity issuances until January 2025, indicating tight liquidity management.
- Small capital raise ($900k net) relative to typical micro-cap operational needs suggests ongoing need for financing.
📋 Key Facts
- Total net proceeds: approximately $900,000.
- Registered Direct Offering: 437,192 shares of common stock at $2.635 per share.
- Private Placement: Issuance of Series E Warrants to purchase up to 437,192 shares at an exercise price of $2.51 per share.
- Placement Agent (H.C. Wainwright & Co., LLC) fees include a 7.5% cash fee and warrants for 32,789 shares at an exercise price of $3.2938.
- The company is prohibited from entering into variable rate transactions involving common stock until December 20, 2025.
- Company may establish/use an at-the-market (ATM) facility starting January 5, 2025.
Phio Pharmaceuticals Corp. announced positive clinical trial progress regarding its lead compound, PH-762. A Safety Monitoring Committee recommended escalating to the next dose concentration in a Phase 1b clinical trial following a review of second-dose cohort safety data.
📋 Key Facts
- Lead compound: PH-762
- Clinical stage: Phase 1b clinical trial
- Safety Monitoring Committee reviewed second dose cohort data
- Recommendation issued to escalate to the next dose concentration
Phio Pharmaceuticals Corp. filed an 8-K to furnish its financial results for the period ended September 30, 2024. The filing includes a press release as Exhibit 99.1 but does not contain specific earnings data within the text provided.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period end date: September 30, 2024
- The filing is a standard disclosure of results of operations and financial condition under Item 2.02.
Phio Pharmaceuticals Corp. announced it will present clinical data from its ongoing Phase 1b clinical trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, TX.
📋 Key Facts
- Clinical data presentation scheduled for November 8-10, 2024.
- Data pertains to an ongoing Phase 1b clinical trial.
- Presentation is occurring at the Society for Immunotherapy of Cancer (SITC) annual meeting.
Phio Pharmaceuticals Corp. filed an 8-K to report its financial results for the period ended June 30, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reported financial results for the period ending June 30, 2024.
- Filing date: August 14, 2024.
- The information provided under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Phio Pharmaceuticals Corp. announced a leadership transition in its finance department, appointing Robert M. Infarinato as the new VP and CFO effective August 1, 2024. Concurrently, the company's current principal accounting officer, Caitlin Kontulis, will cease her role on August 1 and terminate employment on August 31, 2024.
🚩 Red Flags
- Simultaneous departure of the current principal accounting officer and appointment of a new CFO can indicate internal transition volatility.
- The outgoing officer (Kontulis) is transitioning to an 'advisory capacity,' which sometimes suggests a phased exit rather than a standard resignation.
📋 Key Facts
- Robert M. Infarinato appointed as VP, CFO, Principal Financial Officer, and Principal Accounting Officer effective August 1, 2024.
- Infarinato's annual base salary is set at $180,000 with a potential annual bonus of up to 30%.
- Caitlin Kontulis will cease serving as principal accounting officer on August 1, 2024.
- Kontulis' employment is scheduled to terminate on August 31, 2024; she will serve in a part-time advisory capacity thereafter.
Phio Pharmaceuticals Corp. has regained compliance with Nasdaq's minimum bid price requirement following the execution of a 1-for-9 reverse stock split effective July 5, 2024.
🚩 Red Flags
- Reverse stock split implementation is often a sign of extreme downward price pressure and potential delisting risk.
- The necessity of a 1-for-9 split indicates the share price had fallen significantly below Nasdaq's minimum requirements.
📋 Key Facts
- Received written notice from Nasdaq on July 19, 2024, confirming compliance with Rule 5550(a)(2).
- Compliance was achieved via a one-for-nine (1:9) reverse stock split.
- The reverse split became effective on July 5, 2024.
Phio Pharmaceuticals Corp. entered into inducement agreements to encourage holders of existing warrants to exercise them at a significantly reduced price of $5.45 per share. In exchange, the company is issuing new Series C and D warrants, resulting in an expected gross cash infusion of approximately $3.1 million.
🚩 Red Flags
- Significant dilution: Existing warrants with high strike prices (up to $324) are being allowed to exercise at $5.45, representing massive downward pressure on share value.
- Desperation signaling: The use of 'inducement letters' to lower exercise prices is often a sign of urgent liquidity needs.
- Restrictive covenants: The company is prohibited from issuing new equity or filing registration statements for 90 days (or until the stock hits $6.50), limiting future financing flexibility.
📋 Key Facts
- Existing warrants (issued 2020-2023) with exercise prices between $9.72 and $324.00 were reduced to a strike price of $5.45 per share.
- The company is issuing new Series C Warrants (583,098 shares) and Series D Warrants (507,474 shares) at an exercise price of $5.45.
- Expected gross proceeds from the warrant exercise are approximately $3.1 million.
- H.C. Wainwright & Co., LLC is serving as the exclusive placement agent with a 7.5% cash fee and a 1.0% management fee.
- The company must file a resale registration statement within 20 calendar days for the new warrant shares.
Phio Pharmaceuticals Corp. has terminated a previously disclosed purchase agreement with Triton Funds LP to sell up to 95,833 shares for $621,000. The termination follows the company's decision to pursue alternative financing options.
🚩 Red Flags
- Termination of a material financing agreement suggests difficulty in securing capital through existing terms.
- The company is undergoing a 1-for-9 reverse stock split (Red Flag Escalator).
- Stock price ($5.23) was trading below the agreed purchase price ($6.48), indicating market weakness.
- Company explicitly stated it needs to 'pursue alternative financing,' implying an urgent need for cash.
📋 Key Facts
- Termination of Purchase Agreement with Triton Funds LP effective July 3, 2024.
- The original agreement (dated May 16, 2024) was for up to 95,833 shares at $6.48 per share.
- No shares were sold or purchased under the agreement prior to termination.
- A 1-for-9 reverse stock split became effective on July 5, 2024.
- The company's closing price on July 3, 2024, was $5.23 per share, which was below the $6.48 strike price.
Phio Pharmaceuticals Corp. is implementing a 1-for-9 reverse stock split effective July 5, 2024. The move will reduce the number of outstanding shares from approximately 4.6 million to 0.5 million.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing requirements or combat low share prices)
- Significant reduction in float/shares outstanding
📋 Key Facts
- Reverse split ratio: 1-for-9
- Effective date: 12:01 a.m. ET on July 5, 2024
- Shares outstanding reduction: From ~4.6 million to ~0.5 million
- New CUSIP number: 71880W501
- Trading symbol remains 'PHIO' on the Nasdaq Capital Market
- Fractional shares will be settled in cash based on the closing price of the last trading day prior to effectiveness
- Exercise prices for outstanding equity awards and warrants will be adjusted proportionately
Phio Pharmaceuticals Corp. held its 2024 Annual Meeting of Stockholders on June 17, 2024, where shareholders approved several key measures including the election of directors and a reverse stock split proposal.
🚩 Red Flags
- Approval of a reverse stock split (ratio between 1-for-2 and 1-for-9) is often used to regain compliance with minimum bid price requirements for Nasdaq listing.
- The company has relatively low outstanding shares (4,591,700 as of April 26, 2024), which can contribute to volatility.
📋 Key Facts
- Annual Meeting held on June 17, 2024.
- Stockholders approved an amendment to the 2020 Long Term Incentive Plan, increasing available shares by 500,000 to a total of 725,500.
- Stockholders approved a proposal for a reverse stock split with a ratio between 1-for-2 and 1-for-9.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Five directors were elected to serve until the 2025 Annual Meeting.
Phio Pharmaceuticals Corp. announced positive clinical progress regarding its lead compound, PH-762. A Safety Monitoring Committee reviewed Phase 1b data and recommended escalating to the next dose concentration.
📋 Key Facts
- Safety Monitoring Committee (SMC) reviewed safety data from the first dose cohort of the Phase 1b clinical trial for PH-762.
- The SMC recommended escalation to the next dose concentration.
- The announcement was made via press release on May 28, 2024.
Phio Pharmaceuticals Corp. entered into a purchase agreement with Triton Funds LP for the sale of up to 862,500 shares of common stock at $0.72 per share, providing potential gross proceeds of up to $621,000.
🚩 Red Flags
- Small capital raise ($621k) relative to typical micro-cap operational needs, suggesting potential liquidity constraints.
- The agreement includes a 'downside' protection for the buyer (Triton), allowing them to reduce purchase volume if the stock price drops below $0.72.
📋 Key Facts
- Agreement date: May 16, 2024
- Counterparty: Triton Funds LP
- Maximum shares to be sold: 862,500 shares
- Price per share: $0.72
- Total potential gross proceeds: up to $621,000
- Expiration date: November 17, 2024 (or upon sale of all shares)
- Triton ownership cap: 19.99% of outstanding common stock
- Price protection: Triton can reduce share volume if the trading price falls below $0.72 per share.
Phio Pharmaceuticals Corp. filed an 8-K to report its financial results for the quarterly period ended March 31, 2024.
📋 Key Facts
- Reported financial results for the period ending March 31, 2024.
- Filing date: May 9, 2024.
- The information provided under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Phio Pharmaceuticals Corp. filed an 8-K to report its financial results for the fiscal period ended December 31, 2023. The filing serves as a formal announcement of quarterly/annual earnings via an attached press release.
📋 Key Facts
- Reported financial results for the period ended December 31, 2023.
- Filing date: April 2, 2024.
- The information provided under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Phio Pharmaceuticals Corp. received a notification from Nasdaq stating it is non-compliant with the Minimum Bid Price Rule after failing to maintain a $1.00 closing bid price for 30 consecutive business days.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules
- Failure to maintain minimum bid price of $1.00
📋 Key Facts
- Received written notice from Nasdaq on January 24, 2024.
- Non-compliance is specifically regarding Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Rule).
- The company has a 180-day period to regain compliance, which expires on July 22, 2024.
- Compliance can be regained if the stock closes at $1.00 or more for 10 consecutive business days.